Andrea Antonuzzo

Dr. Andrea Antonuzzo

Unit of Medical Oncology 1, Azienda Ospedaliero-Universitaria Pisana, Santa Chiara Hospital, 56126 Pisa, Italy
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ESEnrico Sammarco
Enrico Sammarco
FMFiorella Manfredi
Fiorella Manfredi
ANAmedeo Nuzzo
Amedeo Nuzzo
MFMarco Ferrari
Marco Ferrari
ABAdele Bonato
Adele Bonato
LGLuca Galli
Luca Galli
Immune checkpoint inhibitor-based therapies represent the current standard of care in the first-line treatment of advanced renal cell carcinoma. Despite a clear benefit in survival outcomes, a considerable proportion of patients experience disease progression; prospective data about second-line therapy after first-line treatment with immune checkpoint inhibitors are limited to small phase II studies. As with other solid tumors (such as melanoma and non-small cell lung cancer), preliminary data about the clinical efficacy of rechallenge of immunotherapy (alone or in combination with other drugs) in renal cell carcinoma are beginning to emerge. Nevertheless, the role of rechallenge in immunotherapy in this setting of disease remains unclear and cannot be considered a standard of care; currently some randomized trials are exploring this approach in patients with metastatic renal cell carcinoma. The aim of our review is to summarize main evidence available in the literature concerning immunotherapy rechallenge in renal carcinoma, especially focusing on biological rationale of resistance to immune checkpoint inhibitors, on the published data of clinical efficacy and on future perspectives.

15 April 2021 in Geriatrics
Verified
Journal Article
Open access
PDF file
ATAntonino C Tralongo
Antonino C Tralongo
RFRoberto S. Fratamico
Roberto S. Fratamico
CRChiara Russo
Chiara Russo
ASAndrea Sbrana
Andrea Sbrana
AAAndrea Antonuzzo
Andrea Antonuzzo
MDMarco Danova
Marco Danova
Aging is a well-recognized risk factor for the development of cancer. The incidence of new cancer diagnoses has increased globally given the rising senior population. Many hypotheses for this increased risk have been postulated over decades, including increased genetic and epigenetic mutations and the concept of immunosenescence. The optimal treatment strategies for this population with cancer are unclear. Older cancer patients are traditionally under-represented in clinical trials developed to set the standard of care, leading to undertreatment or increased toxicity. With this background, it is crucial to investigate new opportunities that belong to the most recent findings of an anti-cancer agent, such as immune-checkpoint inhibitors, to manage these daily clinical issues and eventually combine them with alternative administration strategies of antiblastic drugs such as metronomic chemotherapy.

2 June 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
ANAmedeo Nuzzo
Amedeo Nuzzo
SMSimona Manacorda
Simona Manacorda
ESEnrico Sammarco
Enrico Sammarco
ASAndrea Sbrana
Andrea Sbrana
SBSerena Bazzurri
Serena Bazzurri
Gianluca MasiGianluca Masi
Gianluca Masi
Background: Severe acute respiratory syndrome coronavirus 2 disease (COVID-19) has caused a worldwide challenging and threatening pandemic. Multinational, placebo-controlled, observer-blinded trials were conducted since the beginning of pandemic because safe and effective vaccines were needed urgently. In most trials of COVID-19 vaccines patients affected by malignancies or on treatment with immunosuppressive drugs were excluded. Patients and methods: A retrospective monocentric study was conducted at Medical Oncological Unit of Santa Chiara Hospital (Pisa, Italy) in this subset of population to investigate safety and tolerability of COVID-19 vaccines; 377 patients with solid tumor on treatment were enrolled. Vaccine-related adverse events were recorded using a face-to-face questionnaire including a toxicity grading scale. Most of the patients (94%) received mRNA vaccine as indicated by Italian health ministry guidelines. Mean age was 66 years (range 27–87), 62% of the patients were older than 65 years and 68% had at least one additional comorbidity. The majority (86%) of patients were in a metastatic setting and 29% received immunotherapy-based treatment. For statistical analysis, multivariate binary logistic regression models were performed and linear regression models were applied. Results: Adverse events were mild and transient and ended in a few days without any sequelae. No severe or uncommon adverse events were recorded. In multivariate analysis, we found that the female sex was associated with a greater risk of more severe and longer lasting adverse events, and a higher risk of adverse events was found for patients treated with immunotherapy. Conclusions: Our results demonstrate that COVID-19 vaccines were safe and well-tolerated in this population of patients being treated for solid tumors.

10 November 2024 in Cancer Epidemiology
Verified
Journal Article
Closed access
GNGianmauro Numico
Gianmauro Numico
RIRoberto Ippoliti
Roberto Ippoliti
AAAndrea Antonuzzo
Andrea Antonuzzo
LPLorenza Palmero
Lorenza Palmero
PBPaolo Bossi
Paolo Bossi

1 October 2020 in Annals of Oncology
Verified
Journal Article
Closed access
AAAndrea Antonuzzo
Andrea Antonuzzo
PBP. Bossi
P. Bossi
DCD. Cortinovis
D. Cortinovis